← Back to Patent Explorer
US4642233A Expired / Lapsed US ⏱️ 0.0 years remaining

Gastrointestinal drug delivery system comprising a hydrogel reservoir containing a plurality of tiny pills

Assignee: Alza Corp
•
Filing: 1984-01-16
•
Granted: 1987-02-10
•
Expires: 2004-01-16
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A delivery device is disclosed for delivering a beneficial drug to a biological environment of use. The device comprises a hydrogel reservoir containing tiny pills. The tiny pills comprise a wall surrounding a drug core.

Inventors

  • 👤 John Urquhart
  • 👤 Felix Theeuwes

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 14:17
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0053; A61K9/0065; A61K9/20; A61K9/2072; A61K9/2077

Claims Analysis

Total Claims: 6
Claim 1
Independent Claim 192 words
An orally administrable device for the controlled delivery of a beneficial gastrointestional administrable drug to the fluid environment of the gastrointestinal tract over a prolonged period of time, the device comprising: (a) a reservoir shaped and sized for oral admittance into the gastrointestinal tract comprising a pharmaceutically acceptable non-toxic polysaccharide hydrogel that absorbs, imbibes fluid from the gastrointestinal tract and retains fluid within its polysaccharide structure, expands, swells and exhibits a 2 to 50 fold volume increase, said polysaccharide hydrogel a member selected from the group consisting of a noncross-linked polysaccharide hydrogel and a covalent cross-linked polysaccharide hydrogel said hydrogel additionally selected from the group consisting of a naturally occurring polysaccharide hydrogel and a synthetic polysaccharide hydrogel; (b) a plurality of tiny pills dispersed throughout the reservoir comprising the polysaccharide, the tiny pills comprising; (1) a core of a beneficial gastrointestinal administrable drug; and, (2) a wall comprising in a least a part a drug release rate controlling cellulosic polymer having an acetyl content of 21 to 44.8%, that surrounds the core of the beneficial drug and releases the drug when the device is in use into the gastrointestinal tract over time.
Claim 2
Dependent Claim 192 words
An orally administrable device for the controlled delivery of a beneficial gastrointestional administrable drug to the fluid environment of the gastrointestinal tract over a prolonged period of time, the device comprising: (a) a reservoir shaped and sized for oral admittance into the gastrointestinal tract comprising a pharmaceutically acceptable non-toxic polysaccharide hydrogel that absorbs, imbibes fluid from the gastrointestinal tract and retains fluid within its polysaccharide structure, expands, swells and exhibits a 2 to 50 fold volume increase, said polysaccharide hydrogel a member selected from the group consisting of a noncross-linked polysaccharide hydrogel and a covalent cross-linked polysaccharide hydrogel said hydrogel additionally selected from the group consisting of a naturally occurring polysaccharide hydrogel and a synthetic polysaccharide hydrogel; (b) a plurality of tiny pills dispersed throughout the reservoir comprising the polysaccharide, the tiny pills comprising; (1) a core of a beneficial gastrointestinal administrable drug; and, (2) a wall comprising in a least a part a drug release rate controlling cellulosic polymer having an acetyl content of 21 to 44.8%, that surrounds the core of the beneficial drug and releases the drug when the device is in use into the gastrointestinal tract over time.
Claim 3
Dependent Claim 188 words
A gastrointestinal delivery system for the controlled delivery of a beneficial drug to the fluidic environment of the gastrointestinal tract, the gastrointestinal delivery system comprising: (a) means for embedding a plurality of depots comprising a beneficial gastrointestinal drug, said means a reservoir matrix comprising a non-toxic polysaccharide hydrogel that absorbs and imbibes fluid from the gastrointestinal environment and retains fluid within its polysaccharide structure, expands and exhibits a volume increase for retaining the delivery system in the gastrointestinal environment overtime, said polysaccharide hydrogel a member selected from the group consisting of naturally occurring and synthetic pharmaceutically acceptable polysaccharide hydrogels, which polysaccharide hydrogels are additionally a member selected from the group consisting of noncross-linked, covalent cross-linked and ionic cross-linked polysaccharide hydrogels; (b) means for forming the plurality of depots in the reservoir matrix, said means a wall comprising a release rate controlling ethyl cellulose that releases the beneficial gastrointestinal administrable drug over time, which wall surrounds; (c) a beneficial gastrointestinal drug in the depot; and, (d) wherein, when the delivery system is in the gastrointestinal environment, the delivery system delivers the beneficial drug to the gastrointestinal environment over time.
Claim 4
Dependent Claim 188 words
A gastrointestinal delivery system for the controlled delivery of a beneficial drug to the fluidic environment of the gastrointestinal tract, the gastrointestinal delivery system comprising: (a) means for embedding a plurality of depots comprising a beneficial gastrointestinal drug, said means a reservoir matrix comprising a non-toxic polysaccharide hydrogel that absorbs and imbibes fluid from the gastrointestinal environment and retains fluid within its polysaccharide structure, expands and exhibits a volume increase for retaining the delivery system in the gastrointestinal environment overtime, said polysaccharide hydrogel a member selected from the group consisting of naturally occurring and synthetic pharmaceutically acceptable polysaccharide hydrogels, which polysaccharide hydrogels are additionally a member selected from the group consisting of noncross-linked, covalent cross-linked and ionic cross-linked polysaccharide hydrogels; (b) means for forming the plurality of depots in the reservoir matrix, said means a wall comprising a release rate controlling ethyl cellulose that releases the beneficial gastrointestinal administrable drug over time, which wall surrounds; (c) a beneficial gastrointestinal drug in the depot; and, (d) wherein, when the delivery system is in the gastrointestinal environment, the delivery system delivers the beneficial drug to the gastrointestinal environment over time.
Claim 5
Dependent Claim 147 words
A gastrointestinal delivery system for the controlled delivery of a beneficial gastrointestinal administrable drug to the gastrointestinal environment over time, the delivery system comprising: (1) means for housing a plurality of depots comprising a beneficial gastrointestinal administrable drug, said means a body shaped and adapted for oral admittance into the gastrointestinal environment, the body comprising a non-toxic carboxymethyl-cellulose that imbibes fluid from the gastrointestinal environment and retains fluid within its carboxymethylcellulose structure, (2) means for forming the plurality of depots in the delivery system, said means comprising a wall comprising a release rate controlling ethyl cellulose composition that releases the beneficial gastrointestinal administrable drug over time, which (3) wall surrounds the beneficial gastrointestinal administrable drug in the depot; and (4) wherein when the delivery system is in the gastrointestinal environment, the delivery system delivers the beneficial drug at a controlled rate to the gastrointestinal environment over time.
Claim 6
Dependent Claim 147 words
A gastrointestinal delivery system for the controlled delivery of a beneficial gastrointestinal administrable drug to the gastrointestinal environment over time, the delivery system comprising: (1) means for housing a plurality of depots comprising a beneficial gastrointestinal administrable drug, said means a body shaped and adapted for oral admittance into the gastrointestinal environment, the body comprising a non-toxic carboxymethyl-cellulose that imbibes fluid from the gastrointestinal environment and retains fluid within its carboxymethylcellulose structure, (2) means for forming the plurality of depots in the delivery system, said means comprising a wall comprising a release rate controlling ethyl cellulose composition that releases the beneficial gastrointestinal administrable drug over time, which (3) wall surrounds the beneficial gastrointestinal administrable drug in the depot; and (4) wherein when the delivery system is in the gastrointestinal environment, the delivery system delivers the beneficial drug at a controlled rate to the gastrointestinal environment over time.

References Cited (Backward Citations)

US2996431A Cited
US3390050A Cited
GB1182124A Cited
US3867519A Cited
US4178361A Cited
US4167558A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-02-09 1990-08-11 1991-02-10 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-02-09 1994-08-11 1995-02-10 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-02-09 1998-08-11 1999-02-10 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag